The overall purpose of the Cell and Tissue Biology Core is to offer specialized services and reagents to Center members that are not readily available in their individual laboratories. Techniques such as primary liver cell culture and liver perfusion are complex and expensive; they cannot be performed without a very substantial investment in equipment and personnel training. Moreover, 20 years of experience have shown clearly that success is operator-dependent. Laboratories that perform these procedures on an occasional basis only are unlikely to achieve reproducible results. For example, when cell isolates are being prepared on a daily basis, as in the Core, small changes in quality are; readily detected and appropriate analysis is done. This is particularly important when new batches of reagents are introduced that may differ in key properties from those in current use. In this case, careful parallel testing is done to ensure that quality is maintained. Also, reagents such as enzymes for tissue dissociation have a limited shelf life. This is not an issue for a busy Core operation but can be important for the individual laboratory that performs the procedure on an occasional basis only. Thus, centralization of these services within a Core permits: (a) technology transfer to a broad range of Center investigators; (b) standardization of techniques with rigorous quality control; and (c) economy of scale. All of these enhance the productivity and efficiency of the Center as a whole. Another important mission of the Cell and Tissue Biology Core is to improve on existing techniques and develop new services as required by Center members. The history in this regard is noteworthy, as described above, and this remains a fundamental part of the Core?s mission and its service to Center investigators.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Center Core Grants (P30)
Project #
2P30DK026743-21A1
Application #
6675388
Study Section
Special Emphasis Panel (ZDK1)
Project Start
2002-09-30
Project End
2007-05-31
Budget Start
Budget End
Support Year
21
Fiscal Year
2002
Total Cost
Indirect Cost
Name
University of California San Francisco
Department
Type
DUNS #
073133571
City
San Francisco
State
CA
Country
United States
Zip Code
94143
Schwartz, Janice B; Gallagher, J Christopher; Jorde, Rolf et al. (2018) Determination of Free 25(OH)D Concentrations and Their Relationships to Total 25(OH)D in Multiple Clinical Populations. J Clin Endocrinol Metab 103:3278-3288
Qiao, Yu; Xu, Meng; Tao, Junyan et al. (2018) Oncogenic potential of N-terminal deletion and S45Y mutant ?-catenin in promoting hepatocellular carcinoma development in mice. BMC Cancer 18:1093
Sarkar, Monika; Terrault, Norah; Duwaerts, Caroline C et al. (2018) The Association of Hispanic Ethnicity with Nonalcoholic Fatty Liver Disease in Polycystic Ovary Syndrome. Curr Opin Gynecol Obstet 1:24-33
Benet, Leslie Z; Bowman, Christine M; Liu, Shufang et al. (2018) The Extended Clearance Concept Following Oral and Intravenous Dosing: Theory and Critical Analyses. Pharm Res 35:242
Verstraete, Sofia G; Wojcicki, Janet M; Perito, Emily R et al. (2018) Bisphenol a increases risk for presumed non-alcoholic fatty liver disease in Hispanic adolescents in NHANES 2003-2010. Environ Health 17:12
Dave, S; Dodge, J L; Terrault, N A et al. (2018) Racial and Ethnic Differences in Graft Loss Among Female Liver Transplant Recipients. Transplant Proc 50:1413-1423
Maher, Jacquelyn J (2018) Macrophages Steal STING From the Infectious Disease Playbook to Promote Nonalcoholic Fatty Liver Disease. Gastroenterology 155:1687-1688
Cullaro, Giuseppe; Park, Meyeon; Lai, Jennifer C (2018) ""Normal"" Creatinine Levels Predict Persistent Kidney Injury and Waitlist Mortality in Outpatients With Cirrhosis. Hepatology 68:1953-1960
Lee, Brian P; Mehta, Neil; Platt, Laura et al. (2018) Outcomes of Early Liver Transplantation for Patients With Severe Alcoholic Hepatitis. Gastroenterology 155:422-430.e1
Campos-Varela, Isabel; Agudelo, Eliana Z; Sarkar, Monika et al. (2018) Use of a hepatitis C virus (HCV) RNA-positive donor in a treated HCV RNA-negative liver transplant recipient. Transpl Infect Dis 20:

Showing the most recent 10 out of 1119 publications